Cost-Effectiveness of Pharmacogenomics-Guided Prescribing to Prevent Gene-Drug-Related Deaths: A Decision-Analytic Model
Aim: Prospective studies support the clinical impact of pharmacogenomics (PGx)-guided prescribing to reduce severe and potentially fatal adverse effects. Drug-gene interactions (DGIs) preventing potential drug-related deaths have been categorized as "essential" by the Dutch Pharmacogenetic...
Saved in:
Main Authors: | Cathelijne H. van der Wouden (Author), Heiralde Marck (Author), Henk-Jan Guchelaar (Author), Jesse J. Swen (Author), Wilbert B. van den Hout (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Applying Next-Generation Sequencing Platforms for Pharmacogenomic Testing in Clinical Practice
by: Alireza Tafazoli, et al.
Published: (2021) -
Genotyping for HLA Risk Alleles to Prevent Drug Hypersensitivity Reactions: Impact Analysis
by: Lisanne E. N. Manson, et al.
Published: (2021) -
Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines
by: Lisanne E. N. Manson, et al.
Published: (2020) -
The pharmacogenomic landscape of an Indigenous Australian population
by: Sumudu Rangika Samarasinghe, et al.
Published: (2023) -
Pharmacogenomics in Asian Subpopulations and Impacts on Commonly Prescribed Medications
by: Cody Lo, et al.
Published: (2020)